A review of protease inhibitor-induced hyperglycemia

Pharmacotherapy

Volumn 19, Issue 1 I, 1999, Pages 114-117

  Kaufman, Michele B ^a,c   Simionatto, Creuza ^b  

^a Clin Pharm Dept/Drug Info S   (United States)

^b Department of Medecine   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; ETHAMBUTOL; FLUCONAZOLE; GANCICLOVIR; INDINAVIR; ISONIAZID; ISOPHANE INSULIN; ITRACONAZOLE; LAMIVUDINE; NELFINAVIR; ORAL ANTIDIABETIC AGENT; PENTAMIDINE; PROTEINASE INHIBITOR; REPAGLINIDE; RITONAVIR; SAQUINAVIR; TROGLITAZONE; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; ARTICLE; DIABETES MELLITUS; DRUG INDUCED DISEASE; DRUG MONITORING; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; TREATMENT OUTCOME; VIRUS INFECTION;

DRUG MONITORING; HIV INFECTIONS; HUMANS; HYPERGLYCEMIA; PROTEASE INHIBITORS;

EID: 0032894006     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.1.114.30514     Document Type: Article

References (17)

1. Petroski NA. Treating HIV with protease inhibitors. Am Druggist 1996;Oct:50-7.
2. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV Infection in 1997. Updated recommendations of the International AIDS Society - USA panel. JAMA 1997;277:1962-9.
3. Anonymous. Public health advisory on protease inhibitors for HIV treatment. JAMA 1997;278:379.
4. Huff A. Protease inhibitor side effects take people by surprise. GMHC Treatment Issues Newsletter of Experimental AIDS Therapies 1997/1998;12(1):25-7.
5. Dubé MP, Johnson DL, Curry J, et al. Protease inhibitor-associated hyperglycemia. Lancet 1997;350:713-14.
6. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997;127:948.
7. Visnegarwala F, Krause KL, Mushner DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997;127:947.
8. Micromedex, Inc. Drug evaluations [monograph on CD-ROM]. Englewood, CO: Author, 1998.
9. Kilby JM, Tabereaux PB. Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus. J AIDS Hum Retrovir 1998;17:46-50.
10. Pandit MK, Burke J, Gustafson AB, et al. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993;118: 529-39.
11. Kahn CR, Schecter Y. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacologic basis of therapeutics, 8th ed. New York: Pergamon Press, 1990:1465-7.
12. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
13. Abbott Laboratories. Norvir package insert. North Chicago, IL;February 1996.
14. Roche Laboratories. Fortovase package insert. Nutley, NJ;November 1997.
15. Merck & Co. Crixivan package insert. West Point, PA;March 1996.
16. Agouron Pharmaceuticals. Viracept package insert. La Jolla, CA;December 1997.
17. Anonymous. Drug facts and comparisons. St. Louis, MO: Facts and Comparisons, July 1998.